Treatment approach to newly diagnosed diffuse large B-cell lymphoma.
Lyon, France. In Semin Hematol, 30 Apr 2015
High prognostic heterogeneity is observed among patients with DLBCL with long-term survival ranging from 30% to more than 90% according to clinic-biological prognostics such as the International Prognostic Index (IPI) and its subsequent revised variants.
Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity.
New York City, United States. In Semin Immunol, Dec 2014
Since 1996, nine MSMD-causing genes, including seven autosomal (IFNGR1, IFNGR2, STAT1, IL12B, IL12RB1, ISG15, and IRF8) and two X-linked (NEMO, and CYBB) genes have been discovered.
Novel Agents in the Treatment of Chronic Lymphocytic Leukemia: A Review About the Future.
New York City, United States. In Clin Lymphoma Myeloma Leuk, Oct 2014
In this review article we discuss in detail several of the novel agents that are being studied or approved for the treatment of CLL including: phosphatidylinositol 3-kinase inhibitors (idelalisib and IPI-145), Bruton tyrosine kinase inhibitors (ibrutinib), B cell lymphoma 2 inhibitors (ABT-263 and ABT-199), new anti-CD20 monoclonal antibodies (obinutuzumab), cyclin-dependent kinase inhibitors (flavopiridol and dinaciclib), immunomodulators (lenalidomide) and chimeric antigen receptor T-cell therapy.
[Clinical features in DLBCL and translocation BCL2/c-MYC "double hit" lymphoma].
In Acta Med Croatica, Jun 2014
Study results showed that all patients had aggressive characteristics, presence of B symptoms (64%), general patient condition according to ECOG scale ≥ 2 (55%), elevated serum lactate dehydrogenase activity (73%), clinical stage III and IV (82%), extranodal involvement of the disease (73%), and IPI ≥ 2 (73%).